ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel ( CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy | Nature Medicine
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
With 2-pronged filing, Novartis' CAR-T med Kymriah aims to jump into Europe with both feet | Fierce Pharma
The-Unstoppable-CAR-T-Therapy | Esco VacciXcell
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
The-Unstoppable-CAR-T-Therapy | Esco VacciXcell
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
